PTC Therapeutics Long Term Debt

PTC Therapeutics (PTCT) currently reports a long-term debt of $620M as of June 2026. That compares with $460M in the prior-year period — up 36.6% year over year. Use the charts on this page to explore PTC Therapeutics's long-term debt history and peer comparisons.

PTC Therapeutics's long-term debt increased from $460M to $620M — a 36.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PTC Therapeutics reported $620M in long-term debt as of June 2026. That compares with $460M in the prior-year period — up 36.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $620M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PTC Therapeutics, and consider following PTCT for alerts when major investors trade the stock.

PTC Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $620M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PTCT with unrelated industries.